Key points are not available for this paper at this time.
Together, these results suggest that PADI2 may function as an important new biomarker for HER2/ERBB2+ tumors and that Cl-amidine represents a new candidate for breast cancer therapy.
McElwee et al. (Tue,) studied this question.